Empowering mental health professionals with peer-reviewed psychiatric research and insights
Page 2
More JCP Articles
Original Research
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the EMERGENT Trials
February 26, 2025
In pooled analyses, xanomeline/trospium was generally well tolerated. The most common adverse events were mild or moderate, transient, and consistent with the activity of xanomeline and trospium at muscarinic…
Insights
Update on Current & Emerging Treatments for Negative Symptoms in Schizophrenia
February 21, 2025
In this video, Dr. Kantrowitz provides an in-depth update on current and emerging treatments for the negative symptoms of schizophrenia. He discusses symptom classifications, key clinical trials, and potential…
Insights
The Near-Term Future of Muscarinic Agonists and Modulators for Schizophrenia: M1 and/or M4
February 21, 2025
In this video, Dr. Kantrowitz explores the potential of muscarinic acetylcholine receptor (mACHR) agonists and modulators for schizophrenia treatment, with a focus on M1 and M4 receptors. He reviews…
Original Research
Brexpiprazole in Combination with Sertraline and as Monotherapy in PTSD: A Full-Factorial Randomized Clinical Trial
February 19, 2025
In this 10-week study, brexpiprazole in combination with sertraline, but not as monotherapy, demonstrated the potential to be a new efficacious treatment for PTSD.
Original Research
Sequencing Stimulants and Behavioral Parent Training in Multiplex ADHD Families
February 19, 2025
Combination treatment may be helpful for most multiplex ADHD families, and sequencing treatments with behavioral parent training first followed by stimulant medication for the mother may be the most…
